Opinions
David Burrows
Elan Corp.
ELN-N
DON'T BUY
Feb 15, 2002
Questionable accounting practices.
$13.680
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
BUY
Pet adoption enjoyed a boom during the Covid lockdown. Shares have more than doubled since last year's bottom, including jumping 6% today after an excellent quarterly report. Plus, ELN is getting a boost from rising food prices. Today, they announced a blowout quarter with higher than expected earnings and sales and raised full-year guidance.
biotechnology
pharmaceutical
Advertising